Pfizer : PFE

All Pfizer Articles

1518 Articles

Paul Ausick | Dec 26, 2014 at 4:01 PM EST

The 4 Stocks That Pushed Friday’s Market to New Highs

thinkstockDecember 26, 2014: Markets opened higher on Friday on a morning when it was difficult to find any market-moving news…

Jon C. Ogg | Dec 23, 2014 at 11:25 AM EST

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

With investors loving dividends so much, 24/7 always tries to take a look at what the Dogs of the Dow…

Jon C. Ogg | Dec 10, 2014 at 10:35 AM EST

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…

Paul Ausick | Dec 5, 2014 at 4:01 PM EST

The 4 Stocks That Carried the Market on Friday

thinkstockDecember 4, 2014: Markets opened higher on Friday after the federal government released a better-than-expected report on employment. Job gains…

Lee Jackson | Dec 3, 2014 at 8:25 AM EST

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

The U.S. equity market is still a great place to be, and the analysts at Jefferies may have a good…

Lee Jackson | Dec 1, 2014 at 8:25 AM EST

Analyst’s 4 Stocks to Buy With Imminent Catalysts

A new report from Jefferies focuses on four stocks to buy that have impending events that could make a difference…

Paul Ausick | Nov 25, 2014 at 4:01 PM EST

The 4 Stocks That Lifted the DJIA

thinkstockNovember 25, 2014: Markets opened higher on Tuesday but the gains were small heading into the long weekend. The second…

Paul Ausick | Nov 18, 2014 at 9:10 AM EST

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.

Chris Lange | Oct 27, 2014 at 12:40 PM EDT

Pain Therapeutics and Durect Stung by Pfizer Move

Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.

Paul Ausick | Oct 24, 2014 at 4:01 PM EDT

The 4 DJIA Stocks That Boosted the Market

thinkstockOctober 24, 2014: Markets opened slightly higher on Friday, and following a short trip below the break-even line, marched higher…

Jon C. Ogg | Oct 24, 2014 at 8:05 AM EDT

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."

Paul Ausick | Oct 16, 2014 at 4:01 PM EDT

The 4 Stocks That Held the DJIA Down

thinkstockOctober 16, 2014: Markets opened lower on Thursday following a sharp drop in crude oil prices overnight and a better-than-expected…

Jon C. Ogg | Oct 10, 2014 at 9:30 AM EDT

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Short sellers have decided to get out of some of the go-to defensive stocks with high-dividend yields in late September.

Lee Jackson | Oct 1, 2014 at 8:25 AM EDT

Merrill Lynch’s Key Stock Picks for the Fourth Quarter

With or without mid-term elections, the last quarter of 2014 and January of next year could be a bonanza for…

Jon C. Ogg | Sep 25, 2014 at 2:15 PM EDT

5 Defensive Stocks Largely Avoiding the Sell-Off

24/7 Wall St. has tracked several defensive stocks that are not down near as much as the market on Thursday.

1 … 64 65 66 67 68 … 102

Pfizer : PFE

All Pfizer Articles

The 4 Stocks That Pushed Friday’s Market to New Highs

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Pain Therapeutics and Durect Stung by Pfizer Move

The 4 DJIA Stocks That Boosted the Market

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

The 4 Stocks That Held the DJIA Down

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Merrill Lynch’s Key Stock Picks for the Fourth Quarter

5 Defensive Stocks Largely Avoiding the Sell-Off

What It Takes to Retire to Minnesota’s Lake Country at 62 on $900,000

Congress Has Six Years to Save Social Security: Here’s What’s at Stake

Collect $2,000 a Month in Rent and Never Meet a Tenant. These 3 ETFs Handle the Hard Part

What It Takes to Retire to Minnesota's Lake Country at 62 on $900,000

Congress Has Six Years to Save Social Security: Here's What's at Stake

What It Takes to Retire to Minnesota’s Lake Country at 62 on $900,000

Congress Has Six Years to Save Social Security: Here’s What’s at Stake

Pfizer : PFE

All Pfizer Articles

The 4 Stocks That Pushed Friday’s Market to New Highs

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Pain Therapeutics and Durect Stung by Pfizer Move

The 4 DJIA Stocks That Boosted the Market

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

The 4 Stocks That Held the DJIA Down

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Merrill Lynch’s Key Stock Picks for the Fourth Quarter

5 Defensive Stocks Largely Avoiding the Sell-Off

What It Takes to Retire to Minnesota’s Lake Country at 62 on $900,000

Congress Has Six Years to Save Social Security: Here’s What’s at Stake

Collect $2,000 a Month in Rent and Never Meet a Tenant. These 3 ETFs Handle the Hard Part

Featured Reads

What It Takes to Retire to Minnesota's Lake Country at 62 on $900,000

Congress Has Six Years to Save Social Security: Here's What's at Stake